Determination of the Single Nucleotide Polymorphisms C3435 and G2677T in MDR1 and C421A in BCRP in blood samples of patients with inflammatory bowel disease and healthy controls in the swiss population by Hammann, F et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Determination of the Single Nucleotide Polymorphisms C3435 and G2677T
in MDR1 and C421A in BCRP in blood samples of patients with
inflammatory bowel disease and healthy controls in the swiss population
Hammann, F; Hruz, P; Kullak-Ublick, G A; Vavricka, S R; Beglinger, C; Drewe, J; Gutmann, H
Abstract: Aims: P-glycoprotein (P-gp, ABCB1, MDR1) and breast cancer resistance protein (BCRP,
ABCG2) protect the luminal cells of the gastro-intestinal tract from potentially toxic substances. Ge-
netic polymorphisms have previously been associated with disease susceptibility, severity, and treatment
prognosis of inflammatory bowel disease. We investigated the prevalence of frequent single nucleotide
polymorphisms of P-gp and BCRP in the Swiss population in healthy volunteers (n = 17) and patients
newly diagnosed with Crohn’s Disease (CD, n = 34) or Ulcerative Colitis (UC, n = 38). Methods: DNA
from peripheral blood cells was used to assess genotype and allele frequencies of MDR1 C3435T, MDR1
G2677T, and BCRP C421A. Results: Weak associations for BCRP C421A (p < 0.18) and MDR1 G2677T
(p < 0.27) were seen in UC and a trend towards the wild type allele for MDR1 C3435T (p < 0.46). MDR1
3435CC / BCRP 421CC (Χ2: 1.0142, p < 0.30) in UC and MDR1 2677G / BCRP 421A (Χ2: 1.5615,
p < 0.22) also weakly correlated with UC. Results for BCRP C421A in particular justify further study.
Conclusions: Trends towards certain alleles and haplotypes were seen. These merit further studies in
larger subgroups (e.g. by disease stage, therapy refractory patients, etc.).
DOI: 10.4172/2153-0769.1000104
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-75426
Published Version
Originally published at:
Hammann, F; Hruz, P; Kullak-Ublick, G A; Vavricka, S R; Beglinger, C; Drewe, J; Gutmann, H (2012).
Determination of the Single Nucleotide Polymorphisms C3435 and G2677T in MDR1 and C421A in
BCRP in blood samples of patients with inflammatory bowel disease and healthy controls in the swiss
population. Metabolomics, 2:104. DOI: 10.4172/2153-0769.1000104
Metabolomics
ISSN:2153-0769 JOM an open access journal 
Research Article Open Access
Metabolomics : Open Access
Hammann et al. Metabolomics 2012, 2:1
http://dx.doi.org/10.4172/2153-0769.1000104
Volume 2 • Issue 1 • 1000104
In the human gastrointestinal tract, P-gp is expressed predominantly 
apically on the epithelium of small intestine and colon, but also in the 
small biliary and pancreatic ductules [10]. P-gp is therefore seen as a 
contributor to gut mucosal defense and reduced activity is thought to 
be a co-factor in IBD pathogenesis [11].
P-gp is encoded by the MDR1/ABCB1 gene, located on 
Chromosome 7q21.1, and spans over 100 kb. However, MDR1 mRNA 
has a size of 4.7 kDa, implying that only a small percentage of the gene 
actually codes [12]. P-gp is currently the best studied ABC transporter 
and to date 50 single nucleotide polymorphisms (SNPs) have been 
identified, more than half of which reside in the coding region [13-15]. 
This interest stems from its ability to confer multidrug resistance in 
cancer cells by lowering the uptake of anti-cancer drugs [16]. Due to its 
promiscuity and localization, it also affects the bioavailability of many 
other drugs [17] and exposure to one of its substrates can render the 
cell resistant to a wide range of compounds [18]. 
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Abstract
Aims: P-glycoprotein (P-gp, ABCB1, MDR1) and breast cancer resistance protein (BCRP, ABCG2) protect the 
luminal cells of the gastro-intestinal tract from potentially toxic substances. Genetic polymorphisms have previously 
been associated with disease susceptibility, severity, and treatment prognosis of inflammatory bowel disease. We 
investigated the prevalence of frequent single nucleotide polymorphisms of P-gp and BCRP in the Swiss population in 
healthy volunteers (n = 17) and patients newly diagnosed with Crohn’s Disease (CD, n = 34) or Ulcerative Colitis (UC, 
n = 38).
Methods: DNA from peripheral blood cells was used to assess genotype and allele frequencies of MDR1 C3435T, 
MDR1 G2677T, and BCRP C421A. 
Results: Weak associations for BCRP C421A (p < 0.18) and MDR1 G2677T (p < 0.27) were seen in UC and a 
trend towards the wild type allele for MDR1 C3435T (p < 0.46). MDR1 3435CC / BCRP 421CC (Χ2: 1.0142, p < 0.30) 
in UC and MDR1 2677G / BCRP 421A (Χ2: 1.5615, p < 0.22) also weakly correlated with UC. Results for BCRP C421A 
in particular justify further study. 
Conclusions: Trends towards certain alleles and haplotypes were seen. These merit further studies in larger 
subgroups (e.g. by disease stage, therapy refractory patients, etc.). 
Keywords: Crohn‘s Disease; Ulcerative Colitis; Single Nucleotide 
Polymorphism; Haplotype; Genetics; Linkage
Introduction
Inflammatory bowel diseases (IBD) are a group of high-incidence 
inflammatory illness of the intestine, the two most prominent of which 
are ulcerative colitis (UC) and Crohn’s disease (CD) [1]. Both share 
key clinical features (e.g., nausea, maldigestion and malnutrition, and 
associated extra-intestinal manifestations [2]), but also differ in their 
predominant location and the type of inflammation (UC is restricted 
to the mucosa of the colon whereas CD affects the whole length of the 
gastrointestinal tract and all three layers of the epithelium).
There is increasing evidence that the common cause of IBD is a 
malfunction of the intestinal immune system and screening efforts 
support the existence of genetic susceptibility loci [3], which may also 
affect treatment options and prognosis [4]. 
P-glycoprotein (P-gp, MDR1)
P-glycoprotein (P-gp) is a 170 kDa transmembrane protein, 
member of the ATP binding cassette (ABC) family, and a well known 
mammalian efflux transporter that is expressed in many human 
organs with secretory or barrier function, including the liver, and the 
placenta [5]. It is also found on the endothelial capillaries of the brain 
[6], thereby contributing to the blood-brain-barrier function. P-gp is 
considered to protect the cell from xenobiotics and toxic compounds 
and accepts a wide variety of substrates, ranging from small organic 
ions to amino acids and even macromolecules like polysaccharides 
[7,8]. Other physiological functions are still subject of debate, but are 
thought to include regulation of apoptosis, stem-cell differentiation, 
cytokine modulation, and translocation of platelet-activating factor [9].
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Most SNPs in the coding region of P-gp have a relatively low 
frequency (<8%) [15]. With a reported prevalence of 34.3 % in 
Caucasians and 16.9 % in Asians, the SNP C3435T (exon 26) affecting 
the nucleotide binding domain (NBD) 2 is an exception [19]. Even 
though C3435T is a silent SNP, early studies [20] showed a decrease 
in duodenal MDR1 protein expression. Reasons for its effects are still 
subject of debate [21] and a possible link between this SNP and IBD is 
also inconclusive [12]. 
The tri-allelic G2677T/A SNP (Ala893Ser/Thr), known to decrease 
MDR1 transport activity, is also frequently assessed. There are 
indications that the MDR1 G2677T allele is in linkage disequilibrium 
with C3435T, offering a possible explanation for loss of activity 
associated with this silent SNP [22]. MDR1 G2677A is not equally well 
understood as its prevalence is very low (around 1%) [12] and high 
sample sizes are needed to give valid estimates. Some authors therefore 
chose to exclude it in their studies [23,24]. 
Breast Cancer Resistance Protein (BCRP)
Breast cancer resistance protein (BCRP, ABCP, MXR) is the product 
of the ABCG2 gene, located on chromosome 4q22 and spanning > 
66 kb. With reference to other dimer members of the ABC family of 
transporters, which consist of twelve transmembrane domains (TMD) 
and two ATP binding domains (ABD), BCRP has been characterized 
as a half-transporter, as it only has six TMDs and one ABD [25]. 
BCRP is expressed in the epithelium of the small intestine and small 
biliary ducts as well as in the breast and placenta [26]. Like P-gp, it is 
assumed to maintain functional barriers and has been shown to be a 
limiting factor in drug absorption and distribution, e.g. in topotecan, 
doxorubicin, and mitoxantrone [27,28].
The non-synonymous C421A SNP (Q141K) affects the ABD of 
BCRP and substrate binding properties [29]. Its prevalence is quite 
high, with about 30 % in Asian (particularly Han Chinese) and >10 % 
in Caucasian populations while it is rarely seen in African populations 
[30,31]. Strikingly, no associations between the SNP and intestinal 
expression of mRNA or protein could be found [32]. In vitro and in 
vivo studies, on the other hand, have shown this SNP to be disruptive 
of BCRP activity. Clinical trials with diflomotecan, a novel anti-
cancer agent inhibiting topoisomerase I, showed decreased plasma 
concentration in patients heterozygous for this SNP compared to 
wild type [33,34]. Recently, the increased placental crossing of the 
antidiabetic agent glyburide (glibenclamide) has been demonstrated 
in stably transfected human embryonic kidney (HEK)-293 cells 
expressing the polymorphic ABCG2 (Q141K) [35]. 
Synergisms of p-gp and BCRP
ABC transporters, and P-gp and BCRP in particular, play an 
important role in tissue defense. Both are highly expressed in so-called 
side population (SP) cells, a line of primitive cells derived from bone 
marrow stem cells. SP cells have been detected in non-hematopoietic 
tissue and the two efflux pumps are thought to contribute strongly 
to tissue defense and regeneration in many organs [36]. A further 
synergism between P-gp and BCRP lies in their overlapping substrate 
affinity, for example the anti-cancer agent doxorubicin [37], the 
α1-receptor antagonist alfuzosin, and the histamine H2-receptor 
antagonist cimetidine [38]. Also, recent work by Tai et al. [39] indicates 
that both are involved in the clearance of the neurotoxic amyloid 
beta from the brain, thereby protecting individuals from Alzheimer’s 
disease. It may suggest considering these two efflux pumps together in 
studies of pharmacokinetics or pathogenesis.
Haplotype studies
Haplotypes of MDR1 and BCRP have been reported to be associated 
with different inflammatory disorders of the gut. Urcelay et al. [40], for 
example, have identified a susceptibility haplotype (2677T / G3435) 
for CD. Fiedler et al. [41] found a similar association, most notably 
for the MDR1 2677GG / 3435TT haplotype with UC, but not for CD. 
The haplotypes investigated by Ho et al. [23] showed positive (MDR1 
G2677 / 3435T) and negative (MDR1 2677T / C3435) correlations 
with UC, and confirmed the findings of Fiedler et al. [42] Haplotypes 
including BCRP C421A have been less frequently assessed and no 
associations with a combined IBD endpoint are known of to date. 
Methods and Materials
Subjects
We recruited a total of 89 unrelated volunteers (54 female, 35 
male; age: 49.9 years ± range; weight: 72.3 kg ± range; height: 1.68 
m ±range; BMI: 25.5 kg/m2 ± range) in a series of intestinal mucosa 
biopsies and blood samples taken between 2001 and 2007 as part of a 
regular diagnostic procedure. Diagnosis of UC and CD were according 
to current clinical knowledge and based on radiological, endoscopic, 
and histopathological assessment [43]. The study was approved by the 
local ethics committee (Ethik-Kommission Beider Basel, EKBB) and 
informed consent was obtained by all volunteers.
Genotyping
Genomic DNA was isolated from peripheral EDTA-blood using the 
QIAamp DNA blood Kit (Quiagen, Hilden, Germany). We performed 
TaqMan analysis on a 7900HT Sequence Detection System (Applied 
Biosystems, Rotkreuz, Switzerland). 1μl of 10 ng/ μl of genomic 
DNA was added in a well for a multiplex allelic discrimination assay 
along with 9 μl solution consisting of Applied Biosystems TaqMan 
MasterMix, forward primer, reverse primer, probes specific for the 
SNP being examined (see below), and RNase-free water. Samples 
were pipetted onto a 384-well PCR plate (Treff Lab®). The probe stock 
solutions (=100 pmol/µl) were diluted to a concentration of 2 pmol/µl 
for allelic discrimination analysis. During a run, samples were heated 
to 50°C for 2 minutes, then subjected to 95° C for initial denaturation. 
Then, 40 cycles of a two-step PCR were performed at 95° C for 15 s and 
60° C for 60 s.
Primers and probes
The primer set for BCRP C421A was designed with Primer Express 
software (Version 2.0, Applied Biosystems) and ordered at Invitrogen 
(Carlsbad, CA, USA). The sequences for the probes were taken from 
work by Korenaga et al. [44] Table 1. For MDR1 G2677T, a custom 
sequence
probe 1 5´-FAM-CTGCTGAGAACTGTAAGT-MGB-3´
probe 2 5´-VIC`-CTGCTGAGAACTTTAAGT-MGB-3´
forward primer 5'-TGTTGTGATGGGCACTCTGAC-3'
reverse primer 5`-TCATAGTTGTTGCAAGCCGAA-3`
Artificial templates
positive control
(C allele)
5'-TCATAGTTGTTGCAAGCCGAACTGCT
GAGAACTGTAAGTGTCAGAGTGCCCAT
CACAACA-3'
positive control
(A allele)
5'-TCATAGTTGTTGCAAGCCGAACTGC
TGAGAACTTTAAGTGTCAGAGTGCCCA
TCACAACA-3'
Table 1: Primers and Probes used for detection of the Breast Cancer Resistance 
Protein single nucleotide polymorphism C421A.
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assay ordered from Applied Biosystems. The MDR1 C3435T SNP was 
assessed with primers and probes according to work by Eap et al. [45].
Statistical analysis
We calculated the distribution of genotypes from the allele 
frequencies and compared our observations with distributions expected 
from an assumed Hardy-Weinberg equilibrium using Pearson’s Χ2 test 
with two degrees of freedom (df = 2). A p value < 0.05 was considered 
statistically significant. All evaluations were performed using Gnu R 
(http://r-project.org, version 2.8.1) on Microsoft Windows.
Results and Discussion
Determination of genotypes for BCRP C421A, MDR1 
C3435T, and MDR1 G2677T
Distributions of all genotypes were calculated according to the 
Hardy-Weinberg equilibrium. We determined allele frequencies 
for the individual patient groups (CD, UC) and a combination of 
both patient groups (IBD). Odds ratios (OR) are given with a 95 % 
confidence interval (CI) (See Table 2).
MDR1 C3435T
Wild type and mutant alleles were distributed equally in healthy 
controls. This finding is in accordance with previously published 
studies [46]. A slight, but statistically insignificantly increased value of 
54% in the mutant allele T was only seen in patients with UC (OR: 
1.76, CI: 0.30 – 9.78, p< 0.46). Glas et al. [47] and Potocnik et al. [24] 
have reported similar ratios. No difference was seen for CD (OR: 1.36, 
CI: 0.25 – 6.50, p < 0.73) or the combined endpoint IBD (OR: 1.53, CI: 
0.31 – 6.20, p < 0.5).
MDR1 G2677T
Although this SNP is actually tri-allelic, we limited ourselves to the 
T mutant allele due to our relatively small sample size. Other groups 
have done the same [23,24]. At 85%, the wild type allele was more 
prevalent than the mutant allele in healthy controls. Compared to this, 
an association was seen with the wild type allele in UC (93%, OR: 0.42, 
CI: 0.08 – 2.20, p < 0.27) but no difference in either CD (OR: 0.65, CI: 
0.15 – 3.04, p < 0.52) or the combined endpoint IBD (OR: 0.53, CI: 
0.14 – 2.27, p < 0.33). 
BCRP C421A
The wild type was far more abundant (94%) than the mutant allele. 
There is a clear trend towards the mutant allele in UC (OR: 3.51, CI: 
0.63 – 37.03, p < 0.18), albeit not a significant one. Patients with CD 
(OR: 1.68, CI: 0.27 – 18.47, p < 0.71) and the combined group of IBD 
patients (OR: 2.48, CI: 0.50 – 24.43, p< 0.35) showed a similar tendency 
towards the A allele. The lack of significance may be due to the small 
sample population size and hence low statistical power.
Haplotype analysis
We investigated the associations of combined haplotypes of MDR1 
and BCRP SNPs with special attention to the haplotypes previously 
reported on by other authors [40,41,45]. Most strikingly, we found no 
occurrence of the MDR 1*2 haplotype within any of the subgroups. The 
strongest association of a BCRP haplotype was for homozygous MDR1 
3435CC / BCRP 421CC (Χ2: 1.0142, p < 0.30) in UC and MDR1 2677G 
/ BCRP 421A (Χ2: 1.5615, p < 0.22), also in UC. It should be stressed 
that the latter combinations of loci are haplotypes only in a looser 
definition of the term as they are spread over different chromosomes.
Conclusions
We investigated the prevalence of the SNPs MDR1 C3435T, MDR1 
G2677T, and BCRP C421A in blood samples from a Swiss population 
of healthy volunteers and patients suffering from CD or UC. Genotype 
and allele frequencies are similar to those found in other European 
populations. Although the effect of BCRP C421A on IBD is still poorly 
Table 2: Genotype and allele frequencies of BCRP C421A, MDR1 C3435T, and MDR1 G2677T in UC (n=34), CD (n=38), IBD (n=72), and healthy controls (n=17). All 
groups are in Hardy-Weinberg equilibrium, OR = odds ratio; CI = confidence interval
SNP Group Genotype frequencies Allele frequencies p-value (OR; 95% CI)
BCRP C421A
CC CA AA C A
Controls 15 ( 0.88) 2 (0.12) 0 (0.00) 0.94 0.06
UC 23 (0.68) 10 (0.29) 1 (0.03) 0.82 0.18 0.18 (3.51; 0.63-37.03)
CD 31 (0.82) 7 (0.18) 0 (0.00) 0.91 0.09 0.71 (1.68; 0.27 – 18.47)
IBD 54 (0.75) 17 (0.24) 1 (0.01) 0.91 0.09 0.35 (2.48; 0.50 – 24.43)
MDR1 C3435T
CC CT TT C T
Controls 4 (0.24) 9 (0.53) 4 (0.24) 0.50 0.50
UC 5 (0.15) 21 (0.62) 8 (0.24) 0.46 0.54 0.46 (1.76; 0.30 – 9.78)
CD 7 (0.17) 23 (0.61) 8 (0.21) 0.49 0.51 0.73 (1.36; 0.25 – 6.50)
IBD 12 (0.17) 44 (0.61) 16 (0.22) 0.49 0.51 0.50 (1.53; 0.31 – 6.20)
MDR1 G2677T
GG GT TT G T
Controls 12 (0.71) 5 (0.29) 0 (0.00) 0.85 0.15
UC 29 (0.93) 5 (0.15) 0 (0.00) 0.93 0.07 0.27 (0.42; 0.08 – 2.20)
CD 30 (0.79) 7 (0.18) 1 (0.03) 0.88 0.12 0.52 (0.65; 0.15 – 3.04)
IBD 59 (0.82) 12 (0.17) 1 (0.01) 0.88 0.12 0.33 (0.53; 0.14 – 2.27)
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understood, the mutant allele showed the strongest correlation with 
UC of all SNPs in this article. An analysis in a larger sample of the 
population may reveal a statistically significant connection.
In our survey of haplotypes, we found no cases of MDR1 2677T / 
G3435. However, our results justify further research of the prevalence 
of the haplotypes MDR1 C3435T / BCRP C421A and MDR1 G2677T / 
BCRP C421A, both of which were weakly associated with susceptibility 
to UC. Again, a larger sample size would be desirable. 
Data on the role of BCRP C421A in disease pathogenesis is still 
scarce, although this is increasingly coming into focus. Its pathogenetic 
potential has been recently demonstrated in a study in the Han 
Chinese population, showing a strong association between C421A and 
susceptibility to gout [48]. On the other hand, no association with the 
risk for colorectal cancer (for which UC are a known risk factor) could 
be demonstrated in an analysis of the Danish population [49]. The 
effects of BCRP C421A in disease remain ambivalent.
MDR1 as a candidate gene has received more attention in the past. 
In line with our findings of a weak association of the wild type 2677G 
is a current analysis of the Canterbury IBD project [50]. Ardizzone 
et al. [51] found no overall correlation of MDR1 C3435T or G2677T 
with IBD. They did, however, show an association of C3435T a 
subtype of CD (ileo-colonic CD). This selective analytical subgroup 
approach seems very sensible, given the generally weak associations of 
single genetic variants or haplotypes, as a way to increase sensitivity 
without the need of very large sample sizes. Unfortunately, the clinical 
information available to us was not detailed enough to allow for such 
an analysis. This, of course, is largely due to the size of the general 
Swiss population itself. Drawing greater sample sizes would involve a 
considerably longer sampling period and involvement of more centers 
on the national level. It is questionable that sufficient homogeneity as to 
stage of disease, treatment history, and so on, can be achieved in such 
a small population.
The etiology and pathogenesis of IBD remains poorly understood. 
The many factors known to influence disease susceptibility and 
phenotype cannot be pinned down to any single SNP, nor is any 
haplotype likely to discriminate the many facets of these diseases [52]. 
However, knowledge of the activity of efflux transporters at various 
stages of disease and in different populations will ultimately aid in 
the pathogenetic understanding and improved individualized therapy 
based on pharmacogenetic principles. Further studies could focus 
on patient subgroups based on disease progression and response to 
treatment.
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